Check out our most popular compounded medications! Get Started
Phenylpropanolamine HCl 50 mg Oral Capsules are a solid dosage form designed for veterinary use. Each capsule consists of two halves, either gelatin or vegetarian-based, that encapsulate a precise 50 mg dose of the active ingredient, Phenylpropanolamine HCl. This medication is specifically formulated to be easy to administer to animals, ensuring accurate dosing and patient compliance.
These capsules are indicated for the treatment of urinary incontinence in dogs, as Phenylpropanolamine is a sympathomimetic agent that helps to tighten the bladder sphincter muscle. Additionally, Phenylpropanolamine is used as a decongestant and to manage the symptoms of nasal congestion in animals.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Phenylpropanolamine HCl 50 mg Oral Capsules are a solid dosage form designed for veterinary use, specifically tailored for the treatment of conditions such as urinary incontinence in dogs. These capsules are comprised of two halves, either gelatin-based or made from vegetarian alternatives, which encapsulate the active pharmaceutical ingredient, phenylpropanolamine hydrochloride (PPA). This design ensures that the medication is delivered in a precise 50 mg dose, promoting consistent therapeutic effects.
The active compound, phenylpropanolamine, is a sympathomimetic agent that exerts its pharmacological action by stimulating alpha-adrenergic receptors and, to a lesser extent, beta-adrenergic receptors. In the management of urinary incontinence, PPA acts primarily on the urethral sphincter, enhancing its tone and thereby reducing episodes of involuntary urine leakage. This effect is particularly beneficial in spayed female dogs, where estrogen deficiency can lead to a weakening of the urethral sphincter. Phenylpropanolamine is also sometimes used off-label for its decongestant properties due to its vasoconstrictive effects, although this use is less common in veterinary medicine.
It is important for prescribers to consider the potential side effects and contraindications associated with phenylpropanolamine, including hypertension, restlessness, irritability, and potential interactions with other medications. Careful dosing and monitoring are essential, especially in animals with pre-existing cardiovascular conditions or those taking other sympathomimetic drugs. The convenience of the capsule form allows for easy administration, and the encapsulation protects the active ingredient from degradation, ensuring its stability and efficacy until ingestion.
For patients and prescribers considering the use of Phenylpropanolamine HCl 50 mg Oral Capsules for the treatment of urinary incontinence or other applicable conditions in veterinary patients, it is crucial to have a thorough understanding of the animal's medical history and current health status. A veterinarian should be consulted to determine the appropriateness of this medication for a specific patient. If you have any questions or require further information about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is dedicated to providing the highest quality of care and is ready to assist with your pharmaceutical needs.
Phenylpropanolamine HCl (PPA) is a sympathomimetic agent that has been used in veterinary medicine for the treatment of conditions such as urinary incontinence in dogs due to its ability to tighten the bladder sphincter. It is important to be aware of potential drug interactions when administering PPA to ensure the safety and efficacy of the treatment.
PPA should be used with caution in animals that are concurrently receiving monoamine oxidase inhibitors (MAOIs) such as selegiline or antidepressants like amitriptyline, as these can potentiate the effects of sympathomimetic agents and may lead to an increase in blood pressure or other cardiovascular effects. Additionally, the concurrent use of PPA with other sympathomimetic drugs, such as ephedrine or pseudoephedrine, can also increase the risk of systemic side effects including hypertension and arrhythmias.
Animals on tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs) should be monitored closely if PPA is prescribed, as these medications can also interact and lead to increased blood pressure and heart rate. The use of PPA with antihypertensive drugs, such as beta-blockers or ACE inhibitors, may reduce the effectiveness of these medications, and adjustments in dosing may be necessary.
It is also important to consider the effects of PPA on diabetic animals, as it may interfere with insulin requirements. The drug can potentially raise blood sugar levels, necessitating a closer monitoring of diabetic patients and possible adjustment of insulin dosage.
Furthermore, caution is advised when administering PPA to animals with pre-existing conditions such as glaucoma, hyperthyroidism, heart disease, or hypertension, as PPA can exacerbate these conditions.
Lastly, PPA is metabolized in the liver and excreted by the kidneys, so animals with liver or kidney disease may require dose adjustments or more careful monitoring.
It is crucial for prescribers and pet owners to be aware of all medications and supplements the animal is taking to avoid potential interactions. If you have any questions or concerns regarding the use of Phenylpropanolamine HCl 50 mg Oral Capsules for your pet, please reach out to us at Bayview Pharmacy for further guidance and support.
Phenylpropanolamine HCl, commonly referred to as PPA, is an active pharmaceutical ingredient that is used in veterinary medicine to manage urinary incontinence in dogs. The mechanism of action of Phenylpropanolamine revolves around its sympathomimetic properties. As a synthetic sympathomimetic amine, PPA exerts its effects by stimulating the alpha-adrenergic receptors in the smooth muscle of the urethral sphincter. This stimulation leads to an increase in the tone of the urethral sphincter, thereby helping to control urinary incontinence in affected animals.
The Phenylpropanolamine HCl 50 mg Oral Capsules are designed as solid dosage forms, which consist of two halves of gelatin or vegetarian-based shells that encapsulate the precise dose of the medication. These capsules are intended for oral administration. The encapsulation of the active ingredient in a capsule form offers several advantages. Additionally, the capsule shell facilitates easier swallowing for the animal and protects the active ingredient from degradation by environmental factors, such as light and moisture, thus maintaining its stability and potency over time.
Upon oral administration, the capsule shell dissolves in the animal's gastrointestinal tract, releasing the Phenylpropanolamine HCl for absorption. The absorbed PPA then reaches the target alpha-adrenergic receptors in the urethral sphincter, leading to the desired therapeutic effect. It is important for prescribers to consider the appropriate dosage and frequency of administration based on the animal's weight, health status, and the severity of urinary incontinence. Monitoring the animal's response to therapy and adjusting the dosage as needed is also essential to ensure optimal treatment outcomes.
For patients and prescribers considering the use of Phenylpropanolamine HCl 50 mg Oral Capsules for the treatment of urinary incontinence in dogs, it is important to be aware of potential side effects and contraindications. Side effects may include restlessness, irritability, increased heart rate, and loss of appetite. Contraindications include animals with pre-existing heart disease, high blood pressure, or those taking certain medications such as monoamine oxidase inhibitors. A thorough veterinary evaluation is necessary before initiating treatment with PPA.
If you have any questions regarding the Phenylpropanolamine HCl 50 mg Oral Capsules or require further information on the formulation and its use in treating urinary incontinence in dogs, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is dedicated to providing support and guidance to ensure the safe and appropriate use of veterinary medications.
Phenylpropanolamine HCl 50 mg Oral Capsules are a veterinary medication used to treat urinary incontinence in dogs. The active ingredient, Phenylpropanolamine, helps to tighten the bladder sphincter muscle, which helps control urine leakage.
This medication should be administered orally, swallowed whole with some water. Follow the dosage instructions provided by your veterinarian, which usually depend on your pet's weight and the severity of symptoms.
Most dogs tolerate this medication well, but it may not be suitable for dogs with certain medical conditions or those taking specific medications. Always consult with your veterinarian before starting treatment to ensure safety.
The capsules are meant to be taken whole to ensure the correct dosage and maintain the integrity of the medication's release. Opening the capsule and sprinkling it on food is not recommended unless advised by your veterinarian.
If you miss a dose, administer it as soon as you remember. However, if it is almost time for the next scheduled dose, skip the missed dose and continue with the regular dosing schedule. Do not double up doses to make up for the one missed.
No, this formulation is specifically for veterinary use and should not be taken by humans. Always keep medications out of reach of children and use only as directed by a veterinarian for the pet prescribed.
Some potential side effects can include restlessness, irritability, increased heart rate, hypertension, appetite changes, or urinary retention. If you notice any severe or concerning reactions, contact your veterinarian immediately.
Store the capsules in a cool, dry place away from direct sunlight and out of reach of children and pets. Do not store in the bathroom or near the kitchen sink to avoid dampness. Keep the capsule in its original container until use.
Phenylpropanolamine is not currently classified as a controlled substance in veterinary medicine. However, it used to be used in human medications and was subject to control due to misuse. Always use as directed by your veterinarian.
Improvements in urinary incontinence can sometimes be seen within a few days, but it may take longer for the full effects to be noticed. Consult with your veterinarian if you do not observe improvement in your pet's symptoms or if they worsen.
Yes, there can be potential interactions with other drugs, such as ephedrine, tricyclic antidepressants, or certain decongestants and anesthetics. Always inform your veterinarian of all medications and supplements your pet is taking before administering Phenylpropanolamine.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
